United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/619,727	07/15/2003	Wouter E. Roorda	50623.211	7043
Cameron Kerri	7590 06/07/2007 gan		EXAM	INER
Squire, Sanders & Dempsey L.L.P. Suite 300 One Maritime Plaza			AZPURU, CARLOS A	
			ART UNIT	PAPER NUMBER
San Francisco, CA 94111			1615	
			•	
			MAIL DATE	DELIVERY MODE
			06/07/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/619,727	ROORDA ET AL.			
		Examiner	Art Unit			
	·	Carlos A. Azpuru	1615			
	The MAILING DATE of this communication app	·	<u> </u>			
Period fo	or Reply		•			
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES and the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be to discount and will expire SIX (6) MONTHS from the cause the application to become ABANDON	N. imely filed In the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
1)🖂	Responsive to communication(s) filed on 19 M	arch 2007.				
2a)⊠	This action is FINAL . 2b) ☐ This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
5)□ 6)⊠ 7)□	Claim(s) <u>1-24</u> is/are pending in the application. 4a) Of the above claim(s) <u>5,7,13,14 and 17-24</u> Claim(s) is/are allowed. Claim(s) <u>1-4,6, 8-12, 15 and 16</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	is/are withdrawn from considera	tion.			
Applicati	ion Papers					
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. So ion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority (under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachmen	nt(s)					
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔲 Interview Summar Paper No(s)/Mail I				
3) Infor	ce of Draftsperson's Patent Drawing Review (P10-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	5) Notice of Informal 6) Other:				

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of the amendment filed 03/19/2007.

The following rejection is maintained in this action:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-4, 6, 8-12, 15 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 970 711 A2 (Ethicon Inc).

Ethicon Inc disclose polymer coated stents (see Abstract). Non-acrylic polymers such as vinyl halides, polystyrenes and polyoxymethylenes are disclosed for their use in these polymer coatings at [0023]. Multiple coatings are suggested at [0028], with a topcoat suggested at [0029] in order to delay release of the pharmaceutical agent. Anti-inflammatories are set out at [0030]. While Ethicon Inc differs in its lack of specific disclosure of some of the polymers set out in claims 6 and 15, non-acrylic polymers are clearly suggested by the patent for use in providing similar coatings, and for the same art recognized purpose of modifying the release rate of the drug to be delivered. Further, while Ethicon Inc does not set out glass transition temperatures or the

Art Unit: 1615

percentage of water for each polymer, these are measurements for which the ordinary practitioner can either access through reference texts such as the Merk Index, or value which would be expected to overlap given that the same broad classes of polymers are disclosed by the reference. As such, those of ordinary skill would have expected similar therapeutic results from the instantly claimed coating given the disclosure by Ethicon Inc. The instantly claimed coating would have been obvious to one of ordinary skill in the art at the time of invention given the disclosure of Ethicon Inc.

Response to Arguments

Applicant's arguments filed 03/19/2007 have been fully considered but they are not persuasive.

Applicant argues that there is no teaching in Ethicon for one of ordinary skill in the art to select a polymer with a particular glass transition temperature as define in claim1. In particular, applicant argues that there is not suggestion in Ethicon to select a polymer with less than 1 mass % of water controlling the rate of drug release. Further, applicant argues that there is no motivation for selection of polymers of certain glass transition temperatures.

However, as stated in the prior action, applicant is claiming properties which depend upon the particular polymer selected. Again, these values may be referenced in various art recognized chemical manuals. While applicant points to various factors upon

Application/Control Number: 10/619,727

Art Unit: 1615

it: 1615

which glass transition temperature may depend, nothing in the claims points to any specific factor or property beyond the generic description of the polymers. Even when classes of polymers are selected in claim 4, there is nothing in the claim particularly pointing out the molecular weight range or distribution, or ratio of monomers Applicant is therefore arguing limitations not found in the claims.

As such, the reference uses the same polymer classes to overcoat a bioactive containing layer. Applicant's broad claim of acrylic and no-acrylic polymers falls within the scope of the reference, and those of ordinary skill would expect similar rate limiting properties from the coatings instantly claimed. Barring a showing of unexpected results, the instant claims would have been obvious to one of ordinary skill in the art at the time of invention given the teachings of Ethicon.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1615

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Election/Restrictions

This application contains claims 5, 7, 13, 14 and 17-24 drawn to an invention nonelected with traverse in Paper No. 09202006. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlos A. Azpuru whose telephone number is (571) 272-0588. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/619,727 Page 6

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) of 571-272-1000.

Carlos A. Azpuru Primary Examiner Art Unit 1615